Dr Agarwal's Health Care IPO

₹14,070 / 35 shares

RHP/DRHP

Issue Date

--

Price Range

₹382 - ₹402

Lot Size

35

IPO Size

₹3027.26 Cr

Dr Agarwal's Health Care IPO Listing Details

Listing On

4 Feb'25

Issue Price

₹402

Listed Price

₹ 402

Retail Gain/Listing Gain

0.00%

Schedule of Dr Agarwal's Health Care IPO

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

04/02/2025

The IPO of Dr Agarwal’s Health Care Ltd is a 100% book-built issue comprising a fresh issue and offer for sale. While the fresh issue of equity shares aggregates up to ₹300 crore, the offer for sale comprises up to 67,842,284 equity shares.

The company proposes to utilise the net proceeds from the IPO for:

  • Repayment/prepayment, in part or full, of certain of its borrowings
  • General corporate purposes and unidentified inorganic acquisition

The lot size of Dr Agarwal’s Health Care Ltd IPO is 35 and in multiples of 35 thereafter. The table below shows the minimum and maximum lot size retail investors and HNIs can get:

Owing to the high prevalence of eye disorder in India population, eye care is an integral part of the Indian health care system. The eye care market in India has grown at CAGR of 11.5% between Financial Year 2019 and 2024 to reach the value of ₹378 billion in Financial Year 2024. This market includes surgical and non-surgical treatments for patients suffering from various eye disorders. The Indian eye care industry is projected to grow at CAGR of 12-14% between Financial Year 2024 to 2028 to reach market size of ₹550-650 billion.

In this video, we’ll take you through everything you need to know about the company.
Dr. Agarwals Healthcare IPO Review

Kotak Neo

3m 57s

Dr Agarwal’s Health Care Ltd provides a comprehensive range of eye care services, including cataract, refractive and other surgeries. It also offers consultations, diagnoses and non-surgical treatments and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products.

  • The company operates in a regulated industry, and its failure to comply with applicable safety, health, environmental, labor and other regulations, or to obtain or renew approvals, may adversely affect its business, reputation, financial condition, results of operations and cash flows.

  • Majority of its facilities are located in Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these facilities could adversely affect its business, financial condition, results of operations and cash flows.

  • The company’s international operations expose it to management, legal, tax, political and economic risks, and its failure to address such risks could adversely affect its business, results of operations, financial condition and cash flows.

Loading chart...

The anchor investor bidding will take place on 28/1/2024, one day prior to the IPO opening.

IPO Registrar and Book running lead managers

  • Kotak Mahindra Capital Company

  • Morgan Stanley India Company Private Limited

  • Jefferies India Private Limited

  • Motilal Oswal Investment Advisors Limited

The Registrar for the IPO is Kfin Technologies Limited.

The offerings of the company include:

  • Surgeries, including cataract surgeries, refractive surgeries and other surgeries
  • Consultations, diagnoses and non-surgical treatments
  • Sale of opticals, contact lens and accessories
  • Sale of eye care-related pharmaceutical products

The company’s business has demonstrated attractive financial performance over the last three financial years. Its revenue from operations grew from ₹696.078 crore in FY 22 to ₹1332.152 crore in FY 24. Its EBITDA increased from ₹199.822 crore in FY 22 to ₹406.555 crore in FY 24.

According to the CRISIL MI&A Report, Dr Agarwal’s Health Care Ltd had a market share of approximately 25% of the total eye care service chain market in India during the Financial Year 2024. With long-standing operational history, the company endeavours to address all the needs of its patients in their eye treatment journey through a network, which as of September 30, 2024, comprised 209 facilities.

You can check the allotment status of shares either on the website of the Bombay Stock Exchange (BSE) or on the website of the registrar Link Intime India Private Ltd. To check the status on the BSE website:

  • Visit the BSE website
  • Click on “Investor Services” and choose “Application Status Check”
  • Choose the issue type — Equity or Debt
  • Select the Issue Name from the drop-down. The issue name is the company’s name, which is Dr. Agarwal Health Care Ltd
  • Enter your application number or PAN number
  • Check the box which says “I’m not a Robot” and click on “Search” to know the allotment status

To check the status on the registrar’s website:

  • Visit the website of Kfin Technologies Limited
  • Choose ‘Public Issues’ from Investor Services dropdown
  • Choose the name of the company from ‘Select Company’ dropdown
  • Enter any of these — PAN Number, Application Number, DP/Client ID, Account Number / IFSC

Click on Submit to check the status

To apply for this IPO:

  • Step 1: Log in to your Kotak Neo Demat account: Log in to your Demat account to access IPO investments. Next, select the current IPO section
  • Step 2: Specify IPO details: Enter the number of lots and the price you wish to apply for
  • Step 3: Enter UPI ID: After entering your UPI ID, click submit. This will place your bid with the exchange
  • Step 4: Mandate Notification: Your UPI app will receive a mandate notification to block funds
  • Step 5: Approve Request: Your funds will be blocked once you approve the mandate request on your UPI

The Dr Agarwal's Health Care IPO opens for subscription from [-] to [-], with a total issue size of ₹3027.26 Cr. The IPO price band is ₹382 to ₹402 per share with a lot size of 35. The company aims to list the shares on BSE & NSE on 04-02-2025.

The Dr Agarwal's Health Care IPO will open for subscription on [-] and will close on [-] for investors.

The minimum lot size for the Dr Agarwal's Health Care IPO is 35 equity shares, requiring a minimum investment of ₹14070 for retail investors applying in the IPO.

The price band of the Dr Agarwal's Health Care IPO has been fixed at ₹382 to ₹402 per equity share.

You can apply for the Dr Agarwal's Health Care IPO online through the Kotak Neo Website or the Kotak Neo App using UPI or ASBA during the IPO subscription period.

Dr Agarwal's Health Care IPO allotment will take place on [-].

You can check the Dr Agarwal's Health Care IPO allotment status online on the registrar’s website or on the NSE and BSE IPO allotment pages using your application number, PAN, or demat account details.

Dr Agarwal's Health Care shares will list on the stock exchanges on 04-02-2025.

You can find detailed information about the Dr Agarwal's Health Care IPO, including its business operations, financial performance, risk factors, and IPO objectives, in the Draft or Red Herring Prospectus (RHP).

The Dr. Agarwal’s HealthCare Ltd Ltd IPO is a 100% book-built issue comprising a fresh issue and an offer for sale. The total issue size is pegged at TBA. While the fresh issue size is up to ₹300 crore, the offer for sale is at 67,842,284 equity shares.

Information on the lot size is yet not available.

This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Neo Research Team, nor is it a report published by the Kotak Neo Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.